Mitomycin / Vinorelbine in der Therapie des fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms bei chemotherapeutisch vorbehandelten Patienten
Auch gedruckt in der BibliothekW: W-H 12.954
Godde, Felix Johannes
Ressourcen- / MedientypDissertation, Text
Datum der Freischaltung2012-07-04
Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non.small.cell lung cancer (NSCLC). The role of older agents was underattended over the last years. This study presents the combination of Mitomycin C and vinorelbine in pretreated patients. Forty-two patients (stage IIIB and IV, pretreated with platinum-based chemotherapy) received 8 mg m-2 Mitomycin C on day 1 and 25 mg m-2 Vinorelbine on day 1 and 8 of a 28-day cycle. End points were objective tumor response, survival and toxicity. Additionally, QoL was assessed. Five patients (11.9 %) achieved partial responses and 13 patients (31.9 %) stable disease. Progression-free survival was 16 weeks. The median overall survival was 8.5 months. Eleven patients (26.2 %) suffered from grade 3 or 4 neutropenia and four patients (9.5 %) from grade 3 or 4 anaemia. Evaluation of QoL showed that some items amelirated during therapy. The therapeutic concept including Mitomycin C and vinorelbine offers an efficacious and well tolerated regimen with relatively low toxicity. Objective response and survival data correlate with other second-line studies using different medication. As costs of Mitomycin C and vinorelbine are lower compared with current drugs of choice, this regimen is likely to be cost-saving.
MeSHCarcinoma, non-small-cell lung